ENYO Pharma
PrivateLast Round
Series C
Extension
Jun 12, 2025
Total Funding Raised
$117.57M
Company Overview
ENYO Pharma is a biotechnology company that develops innovative small molecule therapeutics by mimicking viral strategies to modulate host cellular functions for the treatment of rare kidney and chronic liver diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Revenue Share, Government Contracts
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
ENYO Pharma Comparables
Compare ENYO Pharma with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Eloxx Pharmaceuticals, Inc. | 76% | |
| Regulus Therapeutics Inc. | 74% | |
| Gilead Sciences | 73% | |
ENYO Pharma Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C Extension | Jun 12, 2025 | ||||
| Series C | Jan 3, 2024 | ||||
| Series B | Jun 4, 2018 | ||||
| Grant | Dec 5, 2016 | ||||
| Series A | Feb 2, 2016 | ||||
Seed | Feb 2, 2015 |
Key People
Founding team and executive leadership
ENYO Pharma Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| European Commission (Horizon Europe) | Grant |
| Andera Partners | Series C Extension, Series C, Series B |
| Inserm Transfert | Series A, Seed, Series B |
| Morningside Ventures | Series A, Series B, Series C Extension, Series C |
| Bpifrance | Series C Extension, Series A, Series C, Series B |
| OrbiMed | Series C Extension, Series C, Series B |
| Vesalius Biocapital Partners | Series C Extension |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jun 12, 2025
ALPESTRIA-1 Phase 2 study shows continued progress in Alport syndrome patients.
- Jun 12, 2025
$37M round raised.
ENYO Pharma Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about ENYO Pharma's valuation, stock price, and market status.